Fidelity Investments
COCP icon

Fidelity Investments’s Cocrystal Pharma COCP Stock Holding History

Fidelity Investments’s Portfolio COCP Stock Details COCP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$337 Buy
+334
New +$345 ﹤0.01% 5194
2024
Q1 		– Sell
-4
Closed -$7 – 5408
2023
Q4 		$7 Sell
4
-183
-98% -$325 ﹤0.01% 5350
2023
Q3 		$350 Buy
187
+96
+105% +$241 ﹤0.01% 4746
2023
Q2 		$217 Buy
91
+87
+2,175% +$211 ﹤0.01% 4894
2023
Q1 		$8 Buy
+4
New +$9 ﹤0.01% 5193

Other funds holding COCP

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TC
T3 Companies New York $76.8M AUM
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Fidelity Investments's COCP Position: Q1 2026 in Review

Fidelity Investments opened a new position in Cocrystal Pharma (COCP) in Q1 2026: 334 shares worth $337. The stake represents ﹤0.01% of the portfolio and ranks #5194 among its holdings. This is a return to the name: Fidelity Investments previously reported a position in COCP as recently as Q4 2023.

Fidelity Investments first reported a position in COCP in Q1 2023 and has held it in 5 quarters since. The position peaked at $350 in Q3 2023. 26 funds tracked by Wall St. Rank hold COCP as of Q1 2026.

  • Fidelity Investments held 334 shares of Cocrystal Pharma worth $337 as of Q1 2026.
  • Cocrystal Pharma was a new Fidelity Investments position in Q1 2026.
  • Cocrystal Pharma made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #5194 holding.
  • Fidelity Investments first reported a position in Cocrystal Pharma in Q1 2023 and has held it in 5 quarters since.
  • Fidelity Investments's Cocrystal Pharma position peaked at $350 in Q3 2023.
  • 26 funds tracked by Wall St. Rank held Cocrystal Pharma as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.